These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 16181547)

  • 1. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma].
    Zhu XL; Zhou XY; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):270-4. PubMed ID: 16181547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.
    Soares P; Trovisco V; Rocha AS; Lima J; Castro P; Preto A; Máximo V; Botelho T; Seruca R; Sobrinho-Simões M
    Oncogene; 2003 Jul; 22(29):4578-80. PubMed ID: 12881714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma.
    Salvatore G; Giannini R; Faviana P; Caleo A; Migliaccio I; Fagin JA; Nikiforov YE; Troncone G; Palombini L; Basolo F; Santoro M
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5175-80. PubMed ID: 15472223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expressions of wildtype-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation].
    Zhu XL; Zhou XY; Zhang TM; Zhu XZ
    Zhonghua Bing Li Xue Za Zhi; 2006 Feb; 35(2):87-91. PubMed ID: 16630482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
    Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
    Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features.
    Durand S; Ferraro-Peyret C; Joufre M; Chave A; Borson-Chazot F; Selmi-Ruby S; Rousset B
    Endocr Relat Cancer; 2009 Jun; 16(2):467-81. PubMed ID: 19208736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
    Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
    Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
    Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
    Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
    J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.
    Rhoden KJ; Unger K; Salvatore G; Yilmaz Y; Vovk V; Chiappetta G; Qumsiyeh MB; Rothstein JL; Fusco A; Santoro M; Zitzelsberger H; Tallini G
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2414-23. PubMed ID: 16595592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
    Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
    Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
    Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M
    J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements.
    Sheu SY; Schwertheim S; Worm K; Grabellus F; Schmid KW
    Mod Pathol; 2007 Jul; 20(7):779-87. PubMed ID: 17464312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The correlation between BRAF mutations, RET/PTC rearrangements and platelet-derived growth factor B expression in papillary thyroid carcinomas].
    Wang P; Wang YG; Zhao WJ; Fu YD; Wang L; Wang F; Zhao SH
    Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):987-91. PubMed ID: 23327964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.
    Joung JY; Kim TH; Jeong DJ; Park SM; Cho YY; Jang HW; Jung YY; Oh YL; Yim HS; Kim YL; Chung JH; Ki CS; Kim SW
    Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Frequency of RET/PTC rearrangement and somatic BRAF mutation in papillary thyroid cancer].
    Rumiantsev PO; Zaletaev DV; Vasil'ev EV; Saenko VA; Il'in AA; Rumiantseva UV; Abrosimov AIu; Medvedev VS
    Vopr Onkol; 2006; 52(2):145-9. PubMed ID: 17195637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas.
    Sadow PM; Heinrich MC; Corless CL; Fletcher JA; Nosé V
    Endocr Pathol; 2010 Jun; 21(2):73-9. PubMed ID: 20012784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan).
    Nakazawa T; Kondo T; Kobayashi Y; Takamura N; Murata S; Kameyama K; Muramatsu A; Ito K; Kobayashi M; Katoh R
    Cancer; 2005 Sep; 104(5):943-51. PubMed ID: 16015630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.